Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gelsectan is a multi-ingredient therapeutic product, classified as a medical device, designed to restore intestinal barrier function and protect the gut mucosa in patients with Irritable Bowel Syndrome (IBS), particularly the diarrhea-predominant phenotype (IBS-D). It contains xyloglucan, a tamarind-derived polysaccharide that acts as a mucoprotectant by forming a physical film over the intestinal epithelium to prevent the adhesion of pathogens and toxins. This effect is reinforced by pea protein and grape seed extract, which help stabilize the protective barrier. Additionally, the formulation includes xylo-oligosaccharides (XOS), which serve as a prebiotic to promote the growth of beneficial gut bacteria. By reducing mucosal permeability and inflammation, Gelsectan aims to alleviate chronic diarrhea, abdominal pain, and bloating associated with IBS and post-infectious IBS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gelsectan.